<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Absci (ABSI) Valuation in Focus Following Partnership With Oracle Cloud and AMD for AI Drug Discovery</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Absci (ABSI) Valuation in Focus Following Partnership With Oracle Cloud and AMD for AI Drug Discovery</h1>
  <ul>
<li>Result: Fair Value of $2.55 (ABOUT RIGHT) See our latest analysis for Absci.</li>
<li>Shares have dropped around 34% over the past year, even as the company has raised fresh funding and added new scientific expertise in its core areas.</li>
<li>Price-to-Book of 2.2x: Is it justified?</li>
<li>This partnership is landing after a year of mixed fortunes for Absci’s stock.</li>
<li>Absci is currently trading at a price-to-book (P/B) ratio of 2.2x, which is in line with the average for the US Biotechs industry but below its immediate peer group.</li>
<li>This offers a snapshot of how much investors are willing to pay for each dollar of net assets.</li>
<li>The price-to-book ratio compares the market price of a company’s shares to its book value per share.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/absci-absi-valuation-focus-following-112745982.html">Source</a> · 2025-09-15T11:27:45+00:00</p>
</body>
</html>